Sharpe P C, Morris T C
Department of Haematology, Belfast City Hospital.
Ulster Med J. 1994 Oct;63(2):144-50.
The use of central venous catheters in patients suffering from haematological disorders has brought enormous benefits, but has been associated with an increase in septicaemia. We have reviewed septic and other complications in 43 patients who received one of three different forms of central venous catheters (type A-Hickman, type B-Portacath, type C-Pasport) during 1991. All complications were reviewed up to 18 months following insertion. The total complication rate was 31% (0.97 per 100 catheter days), and the total sepsis complication rate was 18.8% (0.49 per 100 catheter days). Type A catheters had the greatest sepsis complication rate of 29.5% (0.84 per 100 catheter days), with type B 15% (0.39 per 100 catheter days) and type C 9.9% (0.32 per 100 catheter days). Prophylactic antibiotics on the day of catheter insertion did not reduce the sepsis rate or prolong catheter survival.
在患有血液系统疾病的患者中使用中心静脉导管带来了巨大益处，但与败血症发生率的增加有关。我们回顾了1991年期间接受三种不同类型中心静脉导管（A型-希克曼导管、B型-植入式静脉输液港、C型-护照导管）之一的43例患者的感染及其他并发症情况。对插入导管后长达18个月的所有并发症进行了回顾。总并发症发生率为31%（每100导管日0.97例），败血症总并发症发生率为18.8%（每100导管日0.49例）。A型导管的败血症并发症发生率最高，为29.5%（每100导管日0.84例），B型为15%（每100导管日0.39例），C型为9.9%（每100导管日0.32例）。导管插入当天使用预防性抗生素并未降低败血症发生率，也未延长导管使用寿命。
